References
- Penn I. The changing patterns of post transplant malignancies. Transplant Proc 1991; 23: 1101–1103
- Harwood AR, Osoba D, Hofstader SL, et al. Kaposi’s sarcoma in recipients of renal transplants. Am J Med 1979; 67(5)759–765
- Penn I. Kaposi’s sarcoma in organ transplant recipients. Report of 20 cases. Transplantation 1979; 27(1)8–11
- Duman S, Toz H, Asci G, et al. Successful treatment of post-transplant Kaposi’s sarcoma by reduction of immunosuppression. Nephrol Dial Transplant 2002; 17(5)892–896
- Ecder ST, Sever MS, Yildiz A, et al. Kaposi’s sarcoma after renal transplantation in Turkey. Clin Transplant 1998; 12(5)472–475
- Moray G, Basaran O, Yagmurdur MC, et al. Immunosuppressive therapy and Kaposi’s sarcoma after kidney transplantation. Transplant Proc 2004; 36(1)168–170
- al-Suleiman M Haleen A, AA al Khader. Kaposi’s sarcoma after renal transplant. Transplant Proc 1987; 19: 2243–2244
- Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi’s sarcoma in renal transplant recipients. N Engl J Med 2005; 352(13)1317–1323
- Zmonarski SC, Boratynska M, Rabczynski J, Kazimierczak K, Klinger K. Regression of Kaposi’s sarcoma in renal graft recipients after conversion to sirolimus treatment. Transplant Proc 2005; 37(2)964–966
- Vignot S, Faivre S, Aguirre D, Raymond E. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16(4)525–537
- Luan FL, Ding R, Sharma VK, et al. Rapamycin is an effective inhibitor of human renal cancer metastasis. Kidney Int 2003; 63(3)917–926
- Nepomuceno RR, Balatoni CE, Natkunam Y, et al. Rapamycin inhibits the interleukin 10 signal transduction pathway and the growth of Epstein Barr virus B-cell lymphomas. Cancer Res 2003; 63(15)4472–4480
- Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002; 8(2)128–135
- Hidalgo M, Rowinsky EK. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 2000; 19(56)6680–6686